.webp){kind=logo}
Real-World Data Licensing: A Large Opportunity for RegenMed
January 14, 2025
Real-World Data Licensing: A Large Opportunity for RegenMed
The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth 1. At the same time, there is a strong focus on the importance of real-world data. Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends on an enterprise level.
Everyday physician-patient interactions — correlated to long-term outcomes — are the largest and best source of real world data. In the US alone, over 1 billion such interactions take place each year at 7,400 hospitals, 9,600 ambulatory surgery centers and 340,000 physician group practices 2.
Larger hospital systems are now monetizing their traditional electronic medical record data. However, they are investing heavily to do so. Moreover, the ownership, clinical significance, and reliability of EMR datasets are open to question.
In contrast, Circles represent a clinical grade, low cost and highly efficient method to develop and monetize real-world datasets. Circles datasets are generated through a patented and minimally burdensome closed system. This enable the generation of healthcare datasets which are regularly updated, clinically significant, “hallucination” free, and protected from third-party claims of ownership.
Hospitals and other provider groups are facing strong financial headwinds. Reimbursement rates are declining while costs are increasing. EMR and other IT costs are failing to deliver the promised patient care or economic returns. Circles generate a new and accumulating revenue source at a small fraction of typical IT expenditures.
Moreover, Circles datasets lead to genuine value-based care, health equity, and deeper engagement with physicians and patients. For RegenMed, proprietary and monetizable Circles datasets are the foundation of accelerating enterprise sales.
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Real-World Data Licensing: A Large Opportunity for RegenMed
January 14, 2025
The healthcare data analytics market is worth $64 billion, with a forecasted 21% annual growth 1. At the same time, there is a strong focus on the importance of real-world data. Through its patented Circles platform, RegenMed is well positioned to exploit both of these powerful trends on an enterprise level.
Everyday physician-patient interactions — correlated to long-term outcomes — are the largest and best source of real world data. In the US alone, over 1 billion such interactions take place each year at 7,400 hospitals, 9,600 ambulatory surgery centers and 340,000 physician group practices 2.
Larger hospital systems are now monetizing their traditional electronic medical record data. However, they are investing heavily to do so. Moreover, the ownership, clinical significance, and reliability of EMR datasets are open to question.
In contrast, Circles represent a clinical grade, low cost and highly efficient method to develop and monetize real-world datasets. Circles datasets are generated through a patented and minimally burdensome closed system. This enable the generation of healthcare datasets which are regularly updated, clinically significant, “hallucination” free, and protected from third-party claims of ownership.
Hospitals and other provider groups are facing strong financial headwinds. Reimbursement rates are declining while costs are increasing. EMR and other IT costs are failing to deliver the promised patient care or economic returns. Circles generate a new and accumulating revenue source at a small fraction of typical IT expenditures.
Moreover, Circles datasets lead to genuine value-based care, health equity, and deeper engagement with physicians and patients. For RegenMed, proprietary and monetizable Circles datasets are the foundation of accelerating enterprise sales.
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
1 Healthcare Analytics Market Size, Share, and Trends 2024 to 2034
2 How many hospitals are in the U.S.?; How many ambulatory surgery centers are in the U.S.?; Number of physician group practices by state